325 research outputs found
Systemic immune dysregulation in early breast cancer is associated with decreased plasma levels of both soluble co-inhibitory and co-stimulatory immune checkpoint molecules
Breast cancer cells exploit the up-regulation or down-regulation of immune checkpoint
proteins to evade anti-tumor immune responses. To explore the possible involvement of
this mechanism in promoting systemic immunosuppression, the pre-treatment levels of
soluble co-inhibitory and co-stimulatory immune checkpoint molecules, as well as those
of cytokines, chemokines, and growth factors were measured in 98 newly diagnosed
breast cancer patients and compared with those of 45 healthy controls using multiplex
bead array and ELISA technologies. Plasma concentrations of the co-stimulatory immune
checkpoints, GITR, GITRL, CD27, CD28, CD40, CD80, CD86 and ICOS, as well as the
co-inhibitory molecules, PD-L1, CTLA-4 and TIM-3, were all significantly lower in early
breast cancer patients compared to healthy controls, as were those of HVEM and sTLR-2,
whereas the plasma concentrations of CX3CL1 (fractalkine), CCL5 (RANTES) and those
of the growth factors, M-CSF, FGF-21 and GDF-15 were significantly increased.
However, when analyzed according to the patients’ breast cancer characteristics, these
being triple negative breast cancer (TNBC) vs. non-TNBC, tumor size, stage, nodal status
and age, no significant differences were detected between the plasma levels of the various
immune checkpoint molecules, cytokines, chemokines and growth factors. Additionally,
none of these biomarkers correlated with pathological complete response. This study has
identified low plasma levels of soluble co-stimulatory and co-inhibitory immune checkpoint
molecules in newly diagnosed, non-metastatic breast cancer patients compared to
healthy controls, which is a novel finding seemingly consistent with a state of systemic
immune dysregulation. Plausible mechanisms include an association with elevated levels
of M-CSF and CCL5, implicating the involvement of immune suppressor cells of the M2-macrophage/monocyte phenotype as possible drivers of this state of systemic
immune quiescence/dysregulation.The Cancer Association of South Africa (CANSA).https://www.frontiersin.org/journals/immunologydm2022Immunolog
Regulation of CEACAM1 transcription in human breast epithelial cells
<p>Abstract</p> <p>Background</p> <p>Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) is a transmembrane protein with multiple functions in different cell types. CEACAM1 expression is frequently mis-regulated in cancer, with down-regulation reported in several tumors of epithelial origin and <it>de novo </it>expression of CEACAM1 in lung cancer and malignant melanoma. In this report we analyzed the regulation of CEACAM1 expression in three breast cancer cell lines that varied in CEACAM1 expression from none (MCF7) to moderate (MDA-MB-468) to high (MCF10A, comparable to normal breast).</p> <p>Results</p> <p>Using <it>in vivo </it>footprinting and chromatin immunoprecipitation experiments we show that the <it>CEACAM1 </it>proximal promoter in breast cells is bound in its active state by SP1, USF1/USF2, and IRF1/2. When down-regulated the <it>CEACAM1 </it>promoter remains accessible to USF2 and partially accessible to USF1. Interferon-γ up-regulates CEACAM1 mRNA by a mechanism involving further induction of IRF-1 and USF1 binding at the promoter. As predicted by this analysis, silencing of IRF1 and USF1 but not USF2 by RNAi resulted in a significant decrease in CEACAM1 protein expression in MDA-MB-468 cells. The inactive <it>CEACAM1 </it>promoter in MCF7 cells exhibits decreased histone acetylation at the promoter region, with no evidence of H3K9 or H3K27 trimethylation, histone modifications often linked to condensed chromatin structure.</p> <p>Conclusions</p> <p>Our data suggest that transcription activators USF1 and IRF1 interact to modulate CEACAM1 expression and that the chromatin structure of the promoter is likely maintained in a poised state that can promote rapid induction under appropriate conditions.</p
Cardiovascular magnetic resonance in patients with pectus excavatum compared with normal controls
<p>Abstract</p> <p>Purpose</p> <p>To assess cardiothoracic structure and function in patients with pectus excavatum compared with control subjects using cardiovascular magnetic resonance imaging (CMR).</p> <p>Method</p> <p>Thirty patients with pectus excavatum deformity (23 men, 7 women, age range: 14-67 years) underwent CMR using 1.5-Tesla scanner (Siemens) and were compared to 25 healthy controls (18 men, 7 women, age range 18-50 years). The CMR protocol included cardiac cine images, pulmonary artery flow quantification, time resolved 3D contrast enhanced MR angiography (CEMRA) and high spatial resolution CEMRA. Chest wall indices including maximum transverse diameter, pectus index (PI), and chest-flatness were measured in all subjects. Left and right ventricular ejection fractions (LVEF, RVEF), ventricular long and short dimensions (LD, SD), mid-ventricle myocardial shortening, pulmonary-systemic circulation time, and pulmonary artery flow were quantified.</p> <p>Results</p> <p>In patients with pectus excavatum, the pectus index was 9.3 ± 5.0 versus 2.8 ± 0.4 in controls (P < 0.001). No significant differences between pectus excavatum patients and controls were found in LV ejection fraction, LV myocardial shortening, pulmonary-systemic circulation time or pulmonary flow indices. In pectus excavatum, resting RV ejection fraction was reduced (53.9 ± 9.6 versus 60.5 ± 9.5; P = 0.013), RVSD was reduced (P < 0.05) both at end diastole and systole, RVLD was increased at end diastole (P < 0.05) reflecting geometric distortion of the RV due to sternal compression.</p> <p>Conclusion</p> <p>Depression of the sternum in pectus excavatum patients distorts RV geometry. Resting RVEF was reduced by 6% of the control value, suggesting that these geometrical changes may influence myocardial performance. Resting LV function, pulmonary circulation times and pulmonary vascular anatomy and perfusion indices were no different to controls.</p
Mitochondrial function after global cardiac ischemia and reperfusion: Influences of organelle isolation protocols
Dog hearts were made globally ischemic for 1 hr at normothermia, at 28°C, or at normothermia after perfusion with a hyperkalemic cardioplegia solution. After 1 hr of reperfusion mitochondria were isolated from each heart using three protocols involving: processing (homogenization and centrifugation) exclusively in KCl, Tris-EDTA plus albumin (KEA) solution; homogenizing in KEA but washing mitochondria in EDTA-depleted media (KA); or processing exclusively in EDTA-free medium.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/41745/1/395_2005_Article_BF01907770.pd
- …